enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Merck's Keytruda Improves 5-Year Survival in Lung Cancer - AOL

    www.aol.com/news/mercks-keytruda-improves-5...

    Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

  3. Merck Reveals Mixed Data From Keytruda/Lynparza Regime In ...

    www.aol.com/finance/merck-reveals-mixed-data...

    On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with ...

  4. Merck's Keytruda Secures First FDA-Approval For Rare Form ...

    www.aol.com/mercks-keytruda-secures-first-fda...

    Keytruda plus chemotherapy also significantly improved progression-free survival (PFS) versus chemotherapy alone. The overall response rate (ORR) was significantly higher for Keytruda plus ...

  5. Pembrolizumab - Wikipedia

    en.wikipedia.org/wiki/Pembrolizumab

    Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.

  6. Merck's Keytruda combo succeeds in late-stage trial for ... - AOL

    www.aol.com/news/mercks-keytruda-combo-succeeds...

    (Reuters) -Merck said on Friday its blockbuster immunotherapy Keytruda, in combination with chemoradiotherapy, met the main goal of improving overall survival for newly diagnosed patients with a ...

  7. PD-1 and PD-L1 inhibitors - Wikipedia

    en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

    Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...

  8. Checkpoint inhibitor - Wikipedia

    en.wikipedia.org/wiki/Checkpoint_inhibitor

    Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17] Keytruda is approved to treat melanoma and lung cancer and is produced by Merck .

  9. Merck's Keytruda sets new 5-year survival standard for ... - AOL

    www.aol.com/news/mercks-keytruda-sets-5-survival...

    Keytruda competes with rival drugs from Bristol-Myers Squibb , Roche and others in several types of cancer. Merck's Keytruda sets new 5-year survival standard for advanced lung cancer Skip to main ...